COST-EFFECTIVENESS ANALYSIS OF SWITCHING FROM BASAL INSULIN plus ORAL ANTIDIABETICS-GLP1-RA TO IDEGLIRA IN BRAZIL

被引：0
|
作者：
de Almeida, V [1 ]
Leonart, L. P. [2 ]
Tonin, F. [2 ]
Izar Helfenstein Fonseca, M. [1 ]
Miyamoto Fortes, E. [1 ]
Melo, T. [3 ]
Pititto, L. [1 ]
Gaspar, A. [3 ]
Krakauer, M. [4 ]
机构：
[1] Novo Nordisk, Sao Paulo, SP, Brazil
[2] Heads Hlth, Curitiba, Parana, Brazil
[3] Heads Hlth, Sao Paulo, Brazil
[4] Fac Med ABC, Santo Andre, SP, Brazil
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE295
引用
收藏
页码：S391 / S391
页数：1
相关论文
共 50 条
  • [41] The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting
    Drummond, Russell
    Malkin, Samuel
    Du Preez, Michelle
    Lee, Xin Ying
    Hunt, Barnaby
    DIABETES OBESITY & METABOLISM, 2018, 20 (10): : 2371 - 2378
  • [42] Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands
    Hunt, Barnaby
    Glah, Divina
    van der Vliet, Maarten
    DIABETES THERAPY, 2017, 8 (04) : 753 - 765
  • [43] Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting
    Hu, Ying
    Zheng, Shui-Lian
    Ye, Xiao-Lan
    Shi, Jia-Na
    Zheng, Xiao-Wei
    Pan, Han-Sheng
    Zhang, Yi-Wen
    Yang, Xiu-Li
    Huang, Ping
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (03)
  • [44] Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway
    Huetson, Pernilla
    Palmer, James L.
    Levorsen, Andree
    Fournier, Marie
    Germe, Maeva
    McLeod, Euan
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (08) : 573 - 585
  • [45] Comparison of the cost-effectiveness for basal-bolus therapy of type-1 diabetes using insulin detemir plus insulin aspart or human insulin-based regimens in the Netherlands
    Valentine, WJ
    Wittrup-Jensen, K
    Palmer, AJ
    Roze, S
    VALUE IN HEALTH, 2005, 8 (03) : 255 - 255
  • [46] Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets
    Cannon, Anthony J.
    Bargiota, Alexandra
    Billings, Liana
    Hunt, Barnaby
    Leiter, Lawrence A.
    Malkin, Samuel
    Mocarski, Michelle
    Ranthe, Mattis Flyvholm
    Schiffman, Alisa
    Doshi, Ankur
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (02): : 143 - 153
  • [47] LONG-TERM COST-EFFECTIVENESS OF IDEGLIRA VERSUS BASAL-BOLUS INSULIN AS INTENSIFICATION THERAPIES FOR PEOPLE WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON BASAL INSULIN IN SPAIN: PROJECTIONS BASED ON THE DUAL VII TRIAL
    Ampudia, F. J.
    Mezquita, P.
    de Arellano, Ramirez A.
    Basse, A.
    Hunt, B.
    VALUE IN HEALTH, 2017, 20 (09) : A480 - A480
  • [48] COST-EFFECTIVENESS OF SWITCHING TO BIPHASIC INSULIN ASPART FROM HUMAN PREMIX INSULIN IN PEOPLE WITH TYPE 2 DIABETES IN CHINA
    Xiao, J.
    Bian, X.
    Zhang, Y.
    Yang, L.
    VALUE IN HEALTH, 2014, 17 (03) : A250 - A250
  • [49] Basal insulin plus GLP-1 RA or SGLT2 inhibitor was noninferior to basal-bolus insulin intensification for HbA1c in T2DM
    Boggild, Miranda K.
    Cheung, Angela M.
    ANNALS OF INTERNAL MEDICINE, 2021, 174 (09) : JC106 - JC106
  • [50] Switching From Insulin Bolus Treatment to GLP-1 RAs Added to Continued Basal Insulin in People With Type 2 Diabetes on Basal-Bolus Insulin
    Bolli, Geremia B.
    Porcellati, Francesca
    Meier, Juris J.
    DIABETES CARE, 2020, 43 (10) : 2333 - 2335
12345